Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Engineered nucleases useful for treatment of hemophilia A

Engineered nucleases useful for treatment of hemophilia A

US Patent 11278632 · Granted Mar 22, 2022

Estimated economic value: $3,053,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Genetically-modified T cells comprising a modified intron in the T cell receptor2025
Genetically-modified T cells comprising a modified intron in the T cell receptor2025
Optimized engineered meganucleases having specificity for a recognition sequence2025
Rationally-designed single-chain meganucleases with non-palindromic recognition 2025
Rationally-designed single-chain meganucleases with non-palindromic recognition 2025
Methods for producing a complex transgenic trait locus2025
Methods for producing a complex transgenic trait locus2025
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Polynucleotides encoding engineered meganucleases having specificity for recogni2024
Engineered meganucleases that target human mitochondrial genomes2024